CTLA4 and neoplasm: Indeed, when combined with cytotoxic treatment (AZD6738, an ATR inhibitor and gemcitabine; figure 4F,G) or IOT [anti-CD40 agonist (F), anti-CTLA-4 (C) and anti-PD-L1 (P),FCP; online supplemental figure 7D], the adenosine modulation reduced further the tumor growth rate of the aggressive IOT-resistant 6419c5 tumor model.